| Project/Area Number |
26670423
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Osaka Medical College (2015)
Kansai Medical University (2014) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ITO Seiji 関西医科大学, 医学部, 教授 (80201325)
NOMURA Shosaku 関西医科大学, 医学部, 教授 (20218358)
KURATA Takayasu 関西医科大学, 医学部, 教授 (40340781)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 小細胞肺癌 / 小細胞肺がん / nSR100 / miRNA |
|---|
| Outline of Final Research Achievements |
Small cell lung cancer (SCLC) is a highly malignant form of cancer, which originates from primitive neuroendocrine cells in the lung. Most recently, nSR100 (SRRM4) was highly expressed in SCLC cells correlating with enhancing tumorigenicity and resistance to apoptosis. Inhibition of the PI3K/Akt/mTOR pathway induced nSR100 expression, whereas the specific MEK/ERK inhibitor inhibited nSR100 expression. In this study, we analyzed miRNAs relating nSR100 expression in serum from several patients and nSR100 expression in SCLC cells treated with several compounds including pathway specific inhibitors.
|
